Investment analysts at Citigroup began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Get Free Report) in a research ...

BMO Capital Markets assumed coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a research note issued to ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy ...

Citi initiated coverage of Avidity Biosciences (RNA) with a Buy rating and $70 price target Healthcare policy remains a key biopharma sector ...

BMO Capital initiated coverage of Avidity Biosciences (RNA) with an Outperform rating and $72 price target Avidity’s pipeline includes ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is ...

Del-zota produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44, a Phase 1/2 study in patients with DMD44 (oral presentation) Aravindhan Veerapandiyan, MD ...

Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Outperform recommendation. As of March 5, 2025, the average one-year price target ...

Avidity Biosciences, Inc. (NASDAQ:RNA) has emerged as a frontrunner in the development of RNA-based therapies, leveraging its proprietary antibody-oligonucleotide conjugate (AOC) platform to ...

Analysts have recently evaluated Avidity Biosciences and provided 12-month price targets. The average target is $69.0, accompanied by a high estimate of $72.00 and a low estimate of $65.00. This ...

BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...

Avidity Sponsored Industry Forum Breakfast Event During MDA Conference SOURCE Avidity Biosciences, Inc. The views and opinions expressed herein are the views and opinions of the author and do not ...